AAA USA INC
PharmaAAA USA INC is a pharmaceutical company focused on Oncology. Key products include LUTATHERA.
FDA Novel Drug Designations
(2018)See 1 novel approval →
AAA USA INC's Key Drugs
AAA USA INC's core commercial portfolio centers on LUTATHERA, spanning Oncology — its most strategically important drugs approved in the last 15 years.
AAA USA INC's Recent FDA Approvals
New NDA/BLA approvals for AAA USA INC over the last two years — novel drugs only, excluding generics and label supplements.
AAA USA INC's Therapeutic Areas
AAA USA INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AAA USA INC's Top Competitors
AAA USA INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AAA USA INC Pipeline Snapshot
Active clinical trials for AAA USA INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LUTATHERA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-01-26
- Latest
- 2024-11-26
- Applications
- 1